Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly

PHASE2CompletedINTERVENTIONAL
Enrollment

720

Participants

Timeline

Start Date

February 14, 2018

Primary Completion Date

September 26, 2019

Study Completion Date

September 26, 2019

Conditions
Avian InfluenzaInfluenza Immunisation
Interventions
DRUG

AS03

Oil-in-water emulsion based adjuvant system.

BIOLOGICAL

Inactivated influenza H7N9 vaccine

Monovalent 2017 H7N9 inactivated influenza vaccine

OTHER

Phosphate Buffered Saline (PBS) diluent

Diluent for 2017 Monovalent Inactivated Influenza A/H7N9 virus vaccine (2017 H7N9 IIV)

Trial Locations (5)

27704

Duke Vaccine and Trials Unit, Durham

30030-1705

The Hope Clinic of Emory University, Decatur

52242-2600

University of Iowa - Vaccine Research and Education Unit, Iowa City

21201-1509

University of Maryland, School of Medicine, Center for Vaccine Development and Global Health, Baltimore

98101-1466

Kaiser Permanente Washington Health Research Institute, Seattle

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03312231 - Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly | Biotech Hunter | Biotech Hunter